Novartis CAR-T treatment approved

https://www.reuters.com/article/us-novartis-cancer-idUSKBN19…

The panel unanimously recommended that the Food and Drug Administration approve the drug, tisagenlecleucel, for patients ages 3 to 25 with relapsed B-cell acute lymphoblastic leukemia (ALL), the most common form of U.S childhood cancer.

4 Likes